Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder
American Journal of Therapeutics 2024 Kristine C. Willett, LeDea R. Bond, Amanda M. Morrill et al.
Background: Major depressive disorder (MDD) affects millions of people and is the leading cause of disability worldwide. Patients report decreased quality of life and ability to perform activities of daily living. It is estimated that the current standard of care, which includes pharmacologic therapy with a selective serotonin reuptake inhibitor, is effective in 40%–60%. Additional treatment...